ABOUT US SCIENCE PIPELINE PATIENTS & CAREGIVERS INVESTORS/MEDIA INSIDE SIGILON Our Company At Sigilon, we are pioneering a new class of therapeutics and seeking to develop functional cures for patients with a wide range of chronic diseases. Our Shielded Living TherapeuticsTM platform combines advanced cell engineering with innovations in biocompatible materials, potentially enabling our product candidates to produce a wide range of therapeutic molecules that may be missing or deficient in the body, including proteins, antibodies and enzymes. Our platform technology was inspired by more than a decade of work at MIT by our academic cofounders, Bob Langer and Dan Anderson, and supported by Flagship Pioneering’s strategic vision. Together, this work paved the way for us to build a diverse pipeline spanning rare blood, lysosomal, and endocrine diseases. Your browser doesn't support HTML5 video tag. Our aspiration From cell function to functional cure to create a world without chronic disease. Our team Leadership Board of Directors Founders Scientific Advisory Board Rogerio Vivaldi, M.D., M.B.A Doug Cole, M.D. John Cox, M.B.A. Stephen Oesterle, M.D. Kavita Patel, M.D. Robert Ruffolo, Jr., Ph.D. Eric Shaff, M.B.A. Brooke Story, M.B.A. ©2021 Sigilon Therapeutics, Inc. The marks SIGILON THERAPEUTICS, SIGILON, SHIELDED LIVING THERAPEUTICS, SLTX, AFIBROMER, AFIBROTEK, and our logos are trademarks of Sigilon Therapeutics, Inc. in the U.S. and other countries. All other marks are the property of their respective owners. Privacy Policy

Skip to main navigation ABOUT US SCIENCE PIPELINE PATIENTS & CAREGIVERS INVESTORS/MEDIA INSIDE SIGILON EMAIL ALERTS SIGN UP FOR INVESTOR EMAIL ALERTS Required fields denoted by an asterisk (). Alert type QUOTE SEC FILING EVENT NEWS WEEKLY SUMMARY EMAIL - UNSUBSCRIBE Unsubscribe from all Sigilon Therapeutics, Inc. email alerts. EMAIL ADDRESS INVESTORS/MEDIA Investors/Media Home News & Events Press Releases Events & Presentations Corporate Presentation Stock Information Stock Quote & Chart Historic Price Lookup Analyst Coverage Financials & Filings SEC Filings Quarterly Reports Corporate Governance Documents & Charters Leadership Board of Directors Committee Composition Investor Resources Investor FAQ Email Alerts INVESTOR CONTACT Robert Windsor, Jr., J.D. VP, Head of Investor Relations Sigilon Therapeutics Robert.windsor@sigilon.com 617.586.3837 MEDIA CONTACT Amy Bonanno Solebury Trout abonanno@soleburytrout.com Brandon Hagen Communications Manager Sigilon Therapeutics brandon.hagen@sigilon.com ©2021 Sigilon Therapeutics, Inc. The marks SIGILON THERAPEUTICS, SIGILON, SHIELDED LIVING THERAPEUTICS, SLTX, AFIBROMER, AFIBROTEK, and our logos are trademarks of Sigilon Therapeutics, Inc. in the U.S. and other countries. All other marks are the property of their respective owners. Privacy Policy